Home>>Lipids>> Prostaglandins>>5-Butyl-4-[2,3-difluoro-4-(phenylmethoxy)phenyl]-6-phenyl-2-pyrimidinamine

5-Butyl-4-[2,3-difluoro-4-(phenylmethoxy)phenyl]-6-phenyl-2-pyrimidinamine

Catalog No.GC46682

An mPGES-1 inhibitor

Products are for research use only. Not for human use. We do not sell to patients.

5-Butyl-4-[2,3-difluoro-4-(phenylmethoxy)phenyl]-6-phenyl-2-pyrimidinamine Chemical Structure

Cas No.: 2253745-78-5

Size Price Stock Qty
250 μg
$60.00
In stock
500 μg
$114.00
In stock
1 mg
$180.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com


Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

5-Butyl-4-[2,3-difluoro-4-(phenylmethoxy)phenyl]-6-phenyl-2-pyrimidinamine is an inhibitor of microsomal prostaglandin E synthase-1 (mPGES-1; IC50s = 66 and 2,730 nM for the human and mouse enzymes, respectively).1 It is selective for mPGES-1 over COX-1 but does inhibit COX-2 at 20 µM. It also inhibits LPS-induced prostaglandin E2 production in mouse peritoneal cells (IC50 = 12 nM). In vivo, 5-butyl-4-[2,3-difluoro-4-(phenylmethoxy)phenyl]-6-phenyl-2-pyrimidinamine (25 mg/kg) reduces carrageenan-induced paw edema in rats.

1.Kal?ic, F., Kolman, V., Ajani, H., et al.Polysubstituted pyrimidines as mPGES-1 inhibitors: Discovery of potent inhibitors of PGE2 production with strong anti-inflammatory effects in carrageenan-induced rat paw edemaChemMedChem15(15)1398-1407(2020)

Reviews

Review for 5-Butyl-4-[2,3-difluoro-4-(phenylmethoxy)phenyl]-6-phenyl-2-pyrimidinamine

Average Rating: 5 ★★★★★ (Based on Reviews and 26 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for 5-Butyl-4-[2,3-difluoro-4-(phenylmethoxy)phenyl]-6-phenyl-2-pyrimidinamine

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.